Mono- and disalicylic acid derivatives: PTP1B inhibitors as potential anti-obesity drugs

Add time:08/06/2019    Source:sciencedirect.com

A series of compounds containing one or two salicylic acid moieties were synthesized, and their efficacy to inhibit the phosphohydrolase activity of PTP1B examined. Some of the methylenedisalicylic acid derivatives were potent inhibitors of PTP1B. Of those derivatives, 3c exhibited about a 14-fold selectivity against TC-PTP, and this compound was tested in a mouse model for its efficacy to prevent diet-induced obesity. It effectively suppressed the increases in body weight and adipose mass, without any noticeable toxic effect. The compound also prevented increases in the plasma triglyceride, cholesterol, and nonesterified fatty acid concentrations; thus, expanding its therapeutic potential to other related metabolic diseases, such as hyperlipidemia and hypercholesterolemia.

We also recommend Trading Suppliers and Manufacturers of 5-BROMO-4-FLUOROSALICYLIC ACID (cas 1644-71-9). Pls Click Website Link as below: cas 1644-71-9 suppliers

Prev:A novel pyrrolidinium ionic liquid with 1,1,2,2-tetrafluoro-2-(1,1,2,2-tetrafluoroethoxy)ethanesulfonate anion as a recyclable reaction medium and efficient catalyst for Friedel–Crafts alkylations of indoles with nitroalkenes
Next:Structure-based optimization and biological evaluation of human 20α-hydroxysteroid dehydrogenase (AKR1C1) salicylic acid-based inhibitors)